exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088560 RNA Name: hsa-miR-449a RNA Type: miRNA Chromosome: chr5 Starnd: - Coordinate: Start Site(bp): 55170586 End Site(bp): 55170607 External Links: hsa-miR-449a

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AKAP13 chr15 85380571 85749358 + UBXN2B chr8 58411359 58451501 + ACSL1 chr4 184755595 184826818 - CALM3 chr19 46601074 46610782 + SUPT6H chr17 28662198 28702679 + STK38L chr12 27243968 27325959 + NPTX1 chr17 80466834 80477843 - PPARD chr6 35342558 35428191 + MID1 chrX 10445310 10833654 - PER2 chr2 238244044 238290102 - C2CD5 chr12 22448583 22544546 - GNA12 chr7 2728105 2844308 - DEDD2 chr19 42198598 42220140 - PHF19 chr9 120855651 120894896 - CCDC86 chr11 60842113 60851081 + PRR12 chr19 49591182 49626439 + ATXN2L chr16 28823035 28837237 + MLLT1 chr19 6210381 6279975 - ANGEL1 chr14 76786168 76826246 - CD151 chr11 832887 839831 + NTN4 chr12 95657807 95791152 - DLL1 chr6 170282206 170306565 - ZNF512B chr20 63956704 63969930 - NCOA1 chr2 24491914 24770702 + ZNF623 chr8 143636013 143656418 + HOXB8 chr17 48611377 48615292 - JPH1 chr8 74234700 74321540 - CRTC3 chr15 90529923 90645345 + TMEM109 chr11 60914158 60923443 + ZDHHC17 chr12 76763588 76853696 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001723 chr7 91924202 91948826 + hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000943 chr19 47421744 47440665 + hsa_circ_0000038 chr1 28800065 28802803 + hsa_circ_0001865 chr9 86292641 86293514 - hsa_circ_0001146 chr20 34241449 34246936 - hsa_circ_0001164 chr20 45891031 45923523 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC018521.1 chr17 47945424 47981736 + AC116913.1 chr15 66488658 66492109 - HCG18 chr6 30286690 30327382 - KCNQ1OT1 chr11 2608328 2699994 - LINC00665 chr19 36313067 36331770 - NEAT1 chr11 65422774 65445540 + SNHG7 chr9 136721366 136728184 - TERC chr3 169764520 169765060 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.